Journal article · 2022

Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs

Sung Soo Ahn, Minkyung Han, Inkyung Jung, Hyung Woo Kim

Clinical and Experimental Rheumatology, 41(9), 1908–1916 · Published 18 November 2022 · DOI 10.55563/clinexprheumatol/ins2z2

View at the publisherCite this paper

In brief

“Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs” is a 2022 journal article by Sung Soo Ahn and 3 co-authors, published in Clinical and Experimental Rheumatology. OpenAlex counts 8 citations as of 19 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
8
Most cited in
2024 (4)
Field-weighted impact
1.03
Authors
4

Abstract

OBJECTIVES: Janus kinase inhibitors and biologics (JAKi/biologics) are cornerstone treatments for rheumatoid arthritis (RA). We evaluated the risks of cancers and cardiovascular diseases (CVDs) in patients with seropositive RA (SPRA) treated with JAKi/biologics. METHODS: Patients with new-onset SPRA during 2010-2020 in the national healthcare database were identified. Events of overall and site-specific cancers, as well… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ahn, S. S., Han, M., Jung, I., & Kim, H. W. (2022). Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs. Clinical and Experimental Rheumatology, 41(9), 1908–1916. https://doi.org/10.55563/clinexprheumatol/ins2z2

MLA 9

Ahn, Sung Soo, et al. “Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs.” Clinical and Experimental Rheumatology, vol. 41, no. 9, 2022, pp. 1908–1916. https://doi.org/10.55563/clinexprheumatol/ins2z2.

Chicago

Ahn, Sung Soo, Minkyung Han, Inkyung Jung, and Hyung Woo Kim. 2022. “Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs.” Clinical and Experimental Rheumatology 41 (9): 1908–1916. https://doi.org/10.55563/clinexprheumatol/ins2z2.

Harvard

Ahn, S. S. et al. (2022) ‘Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs’, Clinical and Experimental Rheumatology, 41(9), pp. 1908–1916. doi:10.55563/clinexprheumatol/ins2z2.

IEEE

S. S. Ahn, M. Han, I. Jung, and H. W. Kim, “Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs,” Clinical and Experimental Rheumatology, vol. 41, no. 9, pp. 1908–1916, 2022, doi: 10.55563/clinexprheumatol/ins2z2.

BibTeX

@article{ahn2022cancers,
  title     = {{Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs}},
  author    = {Ahn, Sung Soo and Han, Minkyung and Jung, Inkyung and Kim, Hyung Woo},
  journal   = {Clinical and Experimental Rheumatology},
  year      = {2022},
  volume    = {41},
  number    = {9},
  pages     = {1908--1916},
  doi       = {10.55563/clinexprheumatol/ins2z2},
  url       = {https://doi.org/10.55563/clinexprheumatol/ins2z2}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202311
202444
202522
202611

Its field-weighted citation impact is 1.03: it has been cited 1.03 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • seropositive rheumatoid arthritis
  • JAK inhibitors
  • biologic therapy
  • conventional synthetic DMARDs
  • cancer risk
  • cardiovascular disease
  • deep vein thrombosis
  • pulmonary embolism

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Ahn, S. S., Han, M., Jung, I., & Kim, H. W. (2022). Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs. Clinical and Experimental Rheumatology, 41(9), 1908–1916. https://doi.org/10.55563/clinexprheumatol/ins2z2

How many times has this paper been cited?

8 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Sung Soo Ahn, Minkyung Han, Inkyung Jung, Hyung Woo Kim.

What is the DOI of this paper?

10.55563/clinexprheumatol/ins2z2, permanently at https://doi.org/10.55563/clinexprheumatol/ins2z2. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.